Epinn currently supports CNS tumour and leukemia classification. For CNS tumours, Epinn includes the Sturgeon and Argus-CNS models. For leukemia, Epinn includes the Lamprey and Marlin models. New tumour classification models are under development.

No. Epinn is a premium tumour classification software solution designed for rapid, reliable analysis of methylation sequencing data. Epinn is not open-source or freely available, allowing us to continuously develop and maintain the software and its tumour classification models.

Epinn requires DNA methylation sequencing data to perform tumour classification. The software analyses methylation data to classify tumours using its machine-learning models.

Epinn currently supports Oxford Nanopore Technologies (ONT) sequencing data and Illumina IDAT/EPIC Array data. This allows Epinn to be used with both nanopore sequencing and Illumina methylation array workflows.

The required preprocessing depends on the sequencing platform. ONT: Modified-base calling and alignment using MinKNOW are required. No additional preprocessing is needed before running Epinn. Illumina: Standard processing settings are sufficient for Epinn.

Epinn can run on a standard high-performance workstation. The minimum and recommended specifications are:Minimum specifications (not recommended for real-time sequencing):8-core CPU16 GB RAM200 GB SSD storage Recommended specifications:10-core CPU64 GB RAM300 GB SSD storage For real-time tumour classification during sequencing, we recommend using the recommended system configuration.

No. Epinn is a standalone tumour classification software solution and can be installed without additional software dependencies.

No. Epinn has been designed as a plug-and-play tumour classification solution. Installation and operation do not require specialist bioinformatics knowledge, making Epinn accessible to users without extensive bioinformatics expertise.

No. Epinn does not require command-line expertise. The software is designed with a user-friendly graphical interface, allowing users to perform the required actions using a mouse rather than command-line tools.

Yes. A 1-3 month free trial can be made available for technical validation within your organisation. This allows users to evaluate Epinn with their own data and assess its integration into their existing workflow.

Epinn generally requires a minimum tumour purity of 50% for tumour biopsy samples. For leukemia classification, peripheral blood and bone marrow samples can also be used.